文献速递术前评估与围术期医学产科麻醉

术中地塞米松对糖尿病患者血糖反应的影响:PADDI试验预设分析

The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trial.
PubMed 文献 · Br J Anaesth · 2026-06-16

该预设亚组分析纳入1130例糖化血红蛋白<9.0%的糖尿病患者,比较术中单次8 mg地塞米松与安慰剂对围术期最大血糖及手术部位感染的影响。地塞米松组最大血糖中位数12.5 mM,高于安慰剂组10.3 mM(估计差值1.86 mM,95%CI 1.50-2.22,P<0.001),但手术部位感染风险未增加(11.1% vs 14.4%,RR 0.74,95%CI 0.54-1.01)。

要点

  • 糖尿病患者术中单次8 mg地塞米松使围术期最大血糖中位数升高约1.86 mM。
  • 地塞米松未增加手术部位感染风险,RR 0.74(95%CI 0.54-1.01)。
  • 两组追加胰岛素需求和低血糖事件数无差异。

核心结论

  • 在糖尿病患者中,地塞米松与围术期血糖轻度升高相关,但未增加手术部位感染风险。
  • 研究结果支持在糖尿病患者中使用地塞米松预防术后恶心呕吐。

研究设计与样本

  • PADDI随机安慰剂对照试验的预设亚组分析,采用‘按治疗’分析。
  • 纳入1130例糖尿病患者(平均年龄65.2岁,女性40.7%),糖化血红蛋白<9.0%。

主要发现

  • 地塞米松组(570例)围术期最大血糖中位数12.5 mM(IQR 10.6-15.0),安慰剂组(560例)10.3 mM(IQR 8.8-12.4),估计差值1.86 mM(95%CI 1.50-2.22),P<0.001。
  • 手术部位感染发生率地塞米松组11.1%,安慰剂组14.4%,RR 0.74(95%CI 0.54-1.01)。
  • 年龄、性别、BMI和HbA1c与两组最大血糖水平或手术部位感染发生率无关联。
  • 追加胰岛素需求和低血糖事件数在两组间无差异。

临床怎么用

  • 糖尿病患者术中可考虑单次8 mg地塞米松预防术后恶心呕吐,但需监测围术期血糖。
  • 地塞米松引起的血糖升高幅度中等,未增加手术部位感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Perioperative ADministration of Dexamethasone and Infection (PADDI) randomised placebo-controlled trial showed that a single 8 mg dose of intraoperative dexamethasone had no effect on surgical-site infection within 30 days after nonurgent, noncardiac surgery. Whether dexamethasone increases blood glucose and adverse outcomes in people with diabetes mellitus remains unclear. METHODS: In this preplanned sub-study, 1130 PADDI participants (mean age 65.2 y: 40.7% female) with diabetes mellitus and glycated haemoglobin <9.0% were included in this 'as treated' analysis. The primary outcome was the maximum recorded perioperative blood glucose concentration (mM) within 24 h of anaesthesia induction. RESULTS: The maximum perioperative blood glucose level was 12.5 mM (median, IQR 10.6-15.0) in 570 participants receiving dexamethasone, compared with 10.3 mM (8.8-12.4) in 560 participants receiving placebo (estimated difference 1.86 mM (95% CI 1.50-2.22), P<0.001). There was no evidence of increased risk of surgical-site infection (dexamethasone 11.1% vs placebo 14.4%, risk ratio [RR], 0.74; 95% confidence interval [CI], 0.54-1.01). Age, sex, BMI and HbA1c were not associated with maximum perioperative glucose levels or the incidence of surgical-site infections between the dexamethasone and placebo groups. The requirement for additional insulin and the number of hypoglycaemic episodes did not differ between groups. CONCLUSION: In people with diabetes mellitus, dexamethasone was associated with a modest increase in perioperative blood glucose but not with increased surgical-site infection. These findings support the use of dexamethasone to prevent postoperative nausea and vomiting in people with diabetes mellitus.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Bach LA, Martin C, MacIsaac RJ, et al. The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trial. Br J Anaesth. 2026. PMID: 42303515. doi:10.1016/j.bja.2026.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。